Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells

https://www.globenewswire.com/news-release/2022/04/25/2428069/35334/en/Sunshine-Biopharma-Files-Patent-Application-Covering-Recently-Announced-mRNA-Molecules-Found-To-Be-Effective-At-Destroying-Multidrug-Resistant-Cancer-Cells.html

MONTREAL , April 25, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has filed a provisional patent application in the United States covering the recently communicated mRNA molecules found in pre-clinical trials to be effective at destroying cancer cells grown in culture. The patent application contains composition and utility subject matter pertaining to the structure and sequence of the relevant mRNA molecules.
The cytotoxic effects of the subject mRNA molecules were tested on different cancer cells including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). In contrast to cancer cells, the mRNA molecules had little cytotoxic effects on non-transformed (normal) human cells (HMEC cells). These mRNA molecules are readily adaptable for delivery into patients using the mRNA vaccine technology.
“We are excited about this potential intellectual property position we just staked in connection with our ongoing mRNA-as-therapeutic-agents research,” said Dr. Steve Slilaty , CEO of Sunshine Biopharma . “We believe the potential use of mRNA to treat human diseases opens the door to vast therapeutic possibilities for patients,“ he added.
About Sunshine Biopharma
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 6.2 million people worldwide since it first appeared in December 2019 . Sunshine Biopharma is working on the development of a treatment for COVID-19 and has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4.   In addition, the Company recently expanded its research efforts into finding other PLpro inhibitors by entering into a collaboration agreement with the University of Arizona . The collaboration is focused on determining the in vivo safety, pharmacokinetics, and dose selection properties of three University of Arizona owned PLpro inhibitors, followed by efficacy testing in mice infected with SARS-CoV-2. The Company holds the first option to negotiate for a commercial, royalty-bearing license for all intellectual property developed by University of Arizona under the research project.
In addition to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development of Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada . Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

If you Excited about this coming week and potential for price Explosion to the upside, Drop a Note.

Nice.

Not today Obviously!!

I doubt it will. But show know, Supply and Demand could kick in but that would be for people already holding and those trying to get in cheap.

Unfortunately, we won't see below three for long.

No Volume = No Interest at the current price and are availability of shares at the current price.

Not even 3 million Traded LMAO!!!

I agree but I believe it will be EPIC!! Great things are worth waiting not on retail timing.

Most retail will miss this move Institutional will own the shares, you don't know who they are now, but you will when they are ready to show their face.

If they did that now no one would sell or they, would we forced to Pay more..

I agree but I believe it will be EPIC!! Great things are worth waiting not on retail timing.

Most retail will miss this move Institutional will own the shares, you don't know who they are now, but you will when they are ready to show their face.

If they did that now no one would sell or they, would we forced to Pay more..

the low is 2.23 so it sounds like Lower Lows 20 Days

Come on Sunshine Release Something at the Bell so you can Shut these Block Ruckers Up.

What would be stranger is if they let the price collapse to zero. Get Real.

You can buy, sell or Move on. We all have choices to make.

No idea. No Reddit here.

Wrong again, Never Been on Reddit. It's a Joke. Don't even have an account.

What we see going on here is exactly how Institutional end up have 90% of the shares when the big move happens.

Retail Weak Hands.

Happy Trading today. Maybe a PR since its Thursday last chance for the Week.

The Real Story is the Criminal MM Manipulation.

O/S 14 Million, Float 12.8 Million Period!!

Yea that's exactly why it's not back on the OTC.

You should Watch, Start at 4:20 listen for a minute.

https://marketwirenews.com/news-releases/blockbuster-clinical-results-shine-a-positive-light--7652719222137293.html

No at all wrong Transfer Agent Numbers as of today. But thanks for your feedback.

O/S 14 Million, Float 12.8 Million

If I was short this, I was HAF until that PR Dropped. Bahahah!!

NOOO Lets Sue only when I am on the losing side of the trade. LMAO!!

SBFM didn't Halt the Stock Waste of time.

Clearly Says Halted on a Circuit Breaker to the Upside.

ok. Take it how I can get it. At this Point it only partially made up for the other BS Piece that took the price down because that rise was pretty organic.

Company can't catch a Break.

Did they Halt the Stock??

Could be Paid though, I don't know anymore.

Maybe an 8K today would be nice.

April 19, 2022 02:02 PM ET (BZ Newswire) -- Biotech
Sunshine Biopharma Inc. (NASDAQ:SBFM) might be living the concept of being in the right place at the right time. This Canadian company is currently focusing on three product lines - the SBFM-PL4 COVID-19 treatment, the Adva-27a anticancer compound, and the Essential 9 nutritional supplements - and each is moving forward with positive results.
In February, the company successfully closed an $8 million public offering and was uplisted to the Nasdaq Capital Market. Also, in February, the company entered into an agreement with the University of Arizona to further the development of novel PLpro inhibitors used in its anticancer compound.
Earlier this month, Sunshine Biopharma announced that two of its newly designed mRNA molecules were shown to be effective in terminating and destroying cancer cells grown in culture.
The cytotoxicity tests were performed on different types of cancer cells, including those related to breast, ovarian, and prostate cancer. The company said it planned to file a patent application in connection with the test results.
Benzinga recently spoke with Camille Sebaaly, Sunshine Biopharma’s chief financial officer, about the company’s current and near-future endeavors.
Let’s begin with your COVID treatment. What are your company’s immediate goals with this pursuit?
Camille Sebaaly: Our plan is to deliver a drug that it’s suitable for almost everybody. And with all these coronaviruses that are surfacing, and there is one – Omicron XE – that is very hard for a patient to cope with. We believe our PLpro is extremely good for that, and we believe that it’s the right drug.
Congratulations are in order on the results of your anticancer compound. What is the primary focus of this aspect of your business?
Camille Sebaaly: We are going for multidrug resistance, and now we’re focusing on pancreatic cancer because pancreatic cancer is the most dangerous.
Are you able to offer a preview of your upcoming catalysts, including the human trials for both COVID-19 and the cancer programs?
Camille Sebaaly: I cannot talk about it because it’s not in the public domain yet. It is in process, and it will be announced.
Your company also has the Essential 9 dietary supplement product, which generated about $230,000 during the fiscal year 2021. What plans do you have for this product line?
Camille Sebaaly: We’re planning on doing international marketing – a very aggressive marketing program. We’re looking to sell a lot because this is a very good product – it is called Essential 9 because it contains all the nine amino acids that the body does not cannot make, and a deficiency in one or more of the nine essential amino acid can lead to loss of muscle mass, fatigue, weight gain, a weakened immune system, and reduced general wellness. It’s very good for everybody – I am taking it, and I look way much younger than all my friends my age.
The company was recently in the news over a recent stock selloff, for which some people online blamed an article published by Benzinga. In your view, how did this selloff come about?
Camille Sebaaly: There was no reason to have a selloff. I don’t know what triggered it. I don’t know. The only thing I want to say is I’m sure they misunderstood Benzinga and the short [selling] people took advantage of that, and they carried on with that. That’s all I can say.
In listening to you speak about Sunshine Biopharma, your enthusiasm for your work resonates. What is about working with your company that invigorates you personally?
Camille Sebaaly: We have very good products, and we believe that we have something very interesting. And Dr. Steve Slilaty [the company’s CEO) is, for me, a genius. I’ve been working with him for more than 30 years, and I believe whatever he can do in half an hour takes other scientists at least four to six months to accomplish. He’s a brilliant guy.
I’m very happy and I am very pleased. I work nights and days to deliver for people, and we are very compassionate about what we’re doing.
If we were to pick up this conversation in a year from now, where would you see the company at that time?

Camille Sebaaly: If things go as planned, we have many things in the pipeline. If one of them goes well and does well, God knows where we’ll be next year – the limit is the sky here.
Photo courtesy of Sunshine Biopharma
Price Action: SBFM shares are down 15.3% at $2.93 on the last check Tuesday.
Copyright © 2022 Benzinga (BZ Newswire, http://www.benzinga.com/licensing). Benzinga does not provide investmentadvice. All rights reserved. Write to editorial@benzinga.com with any questions about this content. Subscribe to Benzinga Pro (http://pro.benzinga.com).

News Out that one is not Paid!!

He knows the Research results, BS

Sure, gonna stick in in somebodies Ares..

OHHHH You waiting for the cheapies on a stock that going no where.

Gotcha!!

Two trades for 34164 at close. Obviously, others have not given up.

Why Matters if this is garbage.

Exploring Noncovalent Protease Inhibitors for the Treatment of Severe Acute Respiratory Syndrome and Severe Acute Respiratory Syndrome-Like Coronaviruses

Publication Date: February 24, 2022
https://pubs.acs.org/doi/10.1021/acsinfecdis.1c00631

PLpro is also proficient at cleaving vesper bat, sheep, and northern tree shrew proISG15s with moderate activity toward humans, cows, camels, and mice. Relatively weak activity toward pigs, hedgehogs, and Egyptian fruit bats was observed with no detectable activity against rabbit or fish ISG15. The cleavage rate of several important ISG15s such as humans, mice, and vesper bats by BtSCoV-Rf1.2004 PLpro closely matched what was observed with CoV-1 and CoV-2. (10,29) While some species ISG15s are cleaved more slowly than long-chain K48-Ub, those of BtSCoV-Rf1.2004’s natural hosts R. ferrumequinum and R. sinicus appear to be the preferred substrates.

You should know. My statement Stands.

Exactly!!